Autres langues Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Marché Fermé - Japan Exchange Autres places de cotation 08:34:42 19/04/2024			Varia. 5j.	Varia. 1 janv.
4 636 ^JPY	+2,20 %		+2,39 %	+19,73 %

12:39	Les tensions au Moyen-Orient affectent les marchés boursiers asiatiques	MT
10/04	Le test de diagnostic du cancer du sein métastatique à faible taux de HER2 de Roche obtient le marquage CE	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Middle East Tensions Dent Asian Stock Markets	12:39
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	10/04
Roche erhält CE-Kennung für erstes Brustkrebs-Begleitdiagnostikum	10/04
Scholz setzt auf weitere Pharma-Investitionen in Deutschland	08/04
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	08/04
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours	08/04
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	08/04
AstraZeneca : approbation étendue pour Enhertu aux USA	08/04
AstraZeneca hails neurological data for Ultomiris, Soliris	08/04
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	08/04
Astra hails neurology data; CVS flags cyberattack	08/04
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	08/04
AstraZeneca Wins US Approval for Solid Tumor Treatment	07/04
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB	06/04
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	06/04
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	05/04
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	03/04
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	03/04
Merck : 1ère patiente dans une étude sur raludotatug	03/04
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB	03/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Autres langues

Filtres